User login
Pomalidomide, an investigational third-generation immunomodulatory drug, was more effective when combined with low-dose dexamethasone than high-dose in a clinical trial presented at the annual meeting of the American Society of Hematology.
Patrice Wendling interviewed Dr. Meletios A. Dimopoulos on why reducing toxicity is important in multiple myeloma regimens.
Pomalidomide, an investigational third-generation immunomodulatory drug, was more effective when combined with low-dose dexamethasone than high-dose in a clinical trial presented at the annual meeting of the American Society of Hematology.
Patrice Wendling interviewed Dr. Meletios A. Dimopoulos on why reducing toxicity is important in multiple myeloma regimens.
Pomalidomide, an investigational third-generation immunomodulatory drug, was more effective when combined with low-dose dexamethasone than high-dose in a clinical trial presented at the annual meeting of the American Society of Hematology.
Patrice Wendling interviewed Dr. Meletios A. Dimopoulos on why reducing toxicity is important in multiple myeloma regimens.
